SCHEMBL12224240

SCHEMBL12224240

COc1ccc2nnc(C(F)(F)c3cccc(-c4ncc(N5CCOCC5)cn4)c3)n2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.46
▸ DYRK3 O43781 2/20 0.46
▸ CCNA2 P20248 2/20 0.46
▸ CDK2 P24941 2/20 0.46
▸ DYRK2 Q92630 2/20 0.46
▸ DYRK1B Q9Y463 2/20 0.46
▸ CCNT1 O60563 1/20 0.46
▸ CDK9 P50750 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ ALOX15 P16050 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ MET P08581 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12224251 0.85 DYRK3 (0.42) DYRK1ADYRK3CCNA2CDK2DYRK2
SCHEMBL2452345 0.83 DYRK3 (0.53) DYRK1ADYRK3CCNA2CDK2DYRK2
SCHEMBL12224237 0.80 MET (0.41) KDM4EPIK3CAHPGDHSD17B10CNR2
SCHEMBL12224239 0.79 MET (0.42) DYRK1ADYRK3CCNA2CDK2DYRK2
SCHEMBL1133840 0.78 PIM1 (0.43) KDM4ENPSR1HPGDHSD17B10MET
SCHEMBL12224234 0.77 DYRK1A (0.41) DYRK1ADYRK3CCNA2CDK2DYRK2
SCHEMBL13285382 0.76 RAF1 (0.40) DYRK1ADYRK3CCNA2CDK2DYRK2
SCHEMBL13575023 0.74 MET (0.44) KDM4ENPSR1HPGDHSD17B10MET
SCHEMBL12730491 0.74 MET (0.58) KDM4EHPGDHSD17B10METPIM1
SCHEMBL13575027 0.72 LRRK2 (0.42) KDM4ENPSR1HPGDHSD17B10MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426397-B2 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-04-23 — — US disclosed
US-8426397-B2 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-04-23 — — US disclosed
EP-2367827-B1 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4]TRIAZOLO [4,3-b]PYRIDAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-02-27 — — EP disclosed
US-20110257173-A1 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
US-20110257173-A1 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
WO-2010072301-A1 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257173-A1 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives RET, ERBB2, JAK2 DYRK1A 183/4885DYRK3 244/4885CCNA2 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback